SG 1409
Alternative Names: SG-1409Latest Information Update: 12 Jan 2021
At a glance
- Originator Hangzhou Sumgen Biotech
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Jan 2021 Hangzhou Sumgen Biotech plans to submit an IND application for Cancer in China, in 2021 (Hangzhou Sumgen Biotech pipeline, January 2021)
- 12 Jan 2021 Hangzhou Sumgen Biotech plans to initiate a phase I trial in Cancer in China in 2021 (Hangzhou Sumgen Biotech pipeline, January 2021)
- 30 Dec 2020 Preclinical trials in Cancer in China (Parenteral) (Hangzhou Sumgen Biotech pipeline, January 2021)